Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Janssen gets EC nod for prostate cancer drug Erleada
Erleada is a next generation oral androgen receptor inhibitor approved to treat adult patients with nmCRPC who are at high risk of developing metastatic disease. Apalutamide holds capacity
Erleada is a next generation oral androgen receptor inhibitor approved to treat adult patients with nmCRPC who are at high risk of developing metastatic disease. Apalutamide holds capacity
Juvenescence intends to complete its $100 million Series B financing with the closing of a second tranche in Q1 2019. Juvenescence has now raised over $110 million in
As part of the deal, Sanofi will use the BiXAb platform of Biomunex to generate and enhance bi-specific and multi-specific antibodies. Sanofi will take responsibility for the research,
Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A. Fischetti, Ph.D., a faculty member at The Rockefeller University. Recently, the
KN035 is an investigational programmed cell death ligand-1 (PD-L1) monoclonal antibody which has been exposed to more than 500 patients in multiple clinical trials in US, China and
Charles River said it is reaffirming the commitment to the future of drug discovery by advancing its integrated, innovative early-stage platform. As part of the deal, the partnership
The company submitted a supplemental new drug application (sNDA) with the regulator for new indication of Dextenza. The FDA is expected to complete the review for new indication
FLU-v is being developed by Imutex, hVIVO’s 49% joint venture with the SEEK Group. Following additional analysis of the samples from the study by the National Institute of
Sylvant secured approval in over 40 countries to treat idiopathic multicentric Castleman’s disease (iMCD), which is a subtype of Castleman disease or giant lymph node hyperplasia, lymphoid hamartoma,
Elevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent the diseases of aging. Its first target is